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Abstract
Depressed patients randomized to psychotherapy were compared with those who had been chosen for psychotherapy in a
treatment algorithm, including addition of an antidepressant in case of early nonresponse. There were no differences
between randomized and by-preference patients at baseline in adherence and outcome. About half of the early
nonresponders refused the additional medication. However, no clear effect of medication addition on ultimate outcome
could be demonstrated. In total, 37% of the patients achieved remission. The study suggested that randomization of patients
does not induce a great influence on outcome. It might be warranted to continue an initially ineffective psychotherapy for
depression, because a considerable number of patients do have a pattern of delayed response.
Keywords: brief psychotherapy; depression; long-term psychotherapy; outcome research; personality disorders;
psychoanalytic/psychodynamic therapy; psychotherapist training/supervision/development; psychoses/severe mental
illness
Two meta-analyses indicate that psychotherapy and
pharmacotherapy are equally efficacious for the
acute treatment of mild to moderate depression
(Casacalenda, Perry, & Looper, 2002; De Maat,
Dekker, Schoevers, & de Jonghe, 2006). Relatively
little is known about the efficacy of psychodyna-
mic psychotherapy in the treatment of depression,
because most studies comparing pharmacotherapy
and psychotherapy involve cognitivebehavioural
therapy (e.g., DeRubeis et al., 2005). Over the past
few years, we have sought to fill this gap in
psychotherapy research by directly comparing
short-term psychodynamic supportive psychother-
apy (SPSP), pharmacotherapy, and their combina-
tion in various randomized controlled trials (RCTs;
de Maat et al., 2008).
However, several criticisms have been raised
against the designs of RCTs. It is argued that results
from RCTs are artificial and cannot be generalized
to real-world psychiatric settings (Westen, Novotny,
& Thompson-Brenner, 2004; Rothwell, 2005).
Among other things, the procedure of randomization
fails to match patient with treatment (Brewin &
Bradley, 1989; Parker, 2005). It may exclude highly
motivated patients with a strong preference for a
particular treatment, whereas patients unsuited to
receive a particular treatment are more likely to be
included in a randomization procedure. Therefore, it
is assumed that this selection process may lead to an
underestimation of effectiveness (Bedi et al., 2000;
Howard & Thornicroft, 2006). To remedy this
complication, in our current RCT comparing
SPSP with pharmacotherapy, we opted to add a
by-preference (BP) condition (Brewin & Bradley,
1989). This means that patients refusing to be
randomized were given the treatment of choice.
Another point is that most research data concern
monotreatments, whereas in clinical practice the
addition of medication to psychotherapy is very
common, especially in the case of (early) nonre-
sponse. Indeed, in a previous study, we found that
early nonresponse to psychotherapy for depression
Correspondence concerning this article should be addressed to Henricus L. Van, Mentrum Mental Health Hospital, PO Box 75848, 1070
AV, Amsterdam, The Netherlands. E-mail: rien.van@mentrum.nl
Psychotherapy Research, March 2009; 19(2): 205212
ISSN 1050-3307 print/ISSN 1468-4381 online # 2009 Society for Psychotherapy Research
DOI: 10.1080/10503300802702097
D
o
w
n
lo
ad
ed
 B
y:
 [
Vr
ij
e 
Un
iv
er
si
te
it
, 
Li
br
ar
y]
 A
t:
 1
2:
40
 2
6 
No
ve
mb
er
 2
01
0
carries the risk of ultimate treatment failure, although
at the same time a considerable number of early
nonresponsive patients appear to achieve remission at
the end of treatment as well (Van et al., 2008). There
is some evidence that in interpersonal therapy (IPT)
for depression a sequential strategy with the later
addition of medication is slightly more effective than
combined therapy from the outset (Frank et al.,
2000), but research on this issue is rare. In view of
this state of affairs, we opted for a sequential treat-
ment strategy. It started with monotherapy (psy-
chotherapy or antidepressants) and proceeded to
combined therapy in the case of early nonresponse,
which was defined as less than 30% improvement of
depressive symptoms after 8 weeks of treatment.
Thus, the principal aim of the present study was to
investigate the influence of preference on outcome of
psychotherapy for depression by comparing random
allocation with BP psychotherapy. The effects are
investigated for early response, dropout, and general
efficacy. The second aim was to determine in both
groups the acceptability and surplus value of addi-
tional medication in the case of early nonresponse.
Method
Patients
The study sample consists of consecutively referred
outpatients of Mentrum Mental Health Care, a large
psychiatric teaching hospital in Amsterdam. Inclu-
sion criteria were age between 18 and 65 years,
depressive episode with or without dysthymia (using
the Composite International Diagnostic Interview)
based on Diagnostic and Statistical Manual of Mental
Disorders (fourth edition [American Psychiatric As-
sociation, 1994) criteria, a 17-item Hamilton De-
pression Rating Scale (HAM-D; Hamilton, 1967)
baseline score between 14 and 25 points, and written
informed consent. Exclusion criteria were drug
abuse, psychotic symptoms, participation impossible
as a result of a serious communicative problem (e.g.,
language barrier), pregnancy, hospitalization or day
treatment is unavoidable. Patients who were still
using antidepressants during intake and who met
inclusion criteria were advised to stop the medica-
tion. If they agreed, they were included in the trial; if
not, they were excluded. In addition, all patients who
had used venlafaxine earlier in the present episode
were excluded because this was the first drug to be
administered according to the medication protocol.
Study Design and Procedure
The study compares the efficacy of pharmacother-
apy to SPSP. After intake, the psychiatrist explained
to the patients that both treatments were available
and that the efficacy of both treatments had been
demonstrated and then briefly discussed some basic
characteristics of the treatments. Patients willing to
participate in a study were referred to a research
assistant, who administered the pretreatment
measurements and explained the rationale of a
randomization procedure using a standardized in-
formation form. If patients agreed to select their
treatment by randomization, they were allocated to
either pharmacotherapy or SPSP using block rando-
mization stratified for age and gender. The RCT
comparing psychotherapy and antidepressants di-
rectly has been published elsewhere (Dekker,
Koelen, et al., 2008; Dekker, Van, et al., 2008).
Patients who refused randomization but were never-
theless willing to participate in a study provided they
were given their treatment of choice were entered in
the BP condition. Measurements and treatments
were identical in the randomized and by-preference
groups. At the start of the study, 59 patients were
allotted to the RCT psychotherapy and 60 chose BP
psychotherapy. Because only three patients chose to
start with pharmacotherapy, we are not able to
report on the treatment algorithm that started with
BP antidepressants.
Patients with less than 30% reduction on the
HAM-D after 8 weeks were offered venlafaxine,
75 mg/day, which could be titrated up to a maximum
of 225 mg/day. For patients who responded to
treatment at Week 8, psychotherapy alone was
continued as scheduled.
Treatment
SPSP consisted of 16 sessions, the first eight sessions
weekly, the last every 2 weeks. SPSP is a manual-
based approach (de Jonghe, 2005) focusing on the
affective, behavioural, and cognitive aspects of rela-
tionships. By discerning levels, which depends on the
phase of the therapy and the capacities of the patient,
the therapists may choose more supportive interven-
tions, such as encouraging adaptive coping mechan-
isms, guilt-reducing thoughts, or giving praise, or
interventions to enhance insight, such as confronta-
tion or interpretation. This means that the therapy
can be placed on a variable point on the expressive
supportive continuum (Gabbard, 2005). Therapists
were trained psychiatrists or psychotherapists. They
met regularly to discuss audiotaped sessions and to
ensure adherence to the psychotherapy manual.
Outcome Measures
The primary measurement was the 17-item HAM-D.
The HAM-D was assessed by independent observers.
Raters were trained by de Jonghe, the psychiatrist
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who developed the manual for the Dutch version of
the HAM-D (de Jonghe, 1994) and who has exten-
sive experience in its training and application. Before
being judged competent to assess the HAM-D, raters
needed to score five interviews sufficiently reliably.
During the study the assessors met monthly to discus
videotaped interviews with the supervising psychia-
trist to prevent slippage, but the interrater reliability
was not formally assessed. Secondary outcome mea-
sures were the Clinical Global Impression of severity
(CGI-S) and improvement (CGI-I; Guy, 1976)
provided by the treating clinicians and the Symptom
Checklist-90-Revised (SCL-90) Depression subscale
(Arrindell & Ettema, 1986).
Assessments took place at baseline and Weeks 8,
16, and 24. On the primary outcome measure,
efficacy was expressed both in terms of mean
differences in HAM-D scores and in success rates.
The latter was defined as response rate (50%
reduction on the HAM-D) and remission rate
(HAM-D57). On the secondary measurements,
only success rates are given. They are defined as a
CGI-S and a CGI-I score of 1 (very much improved)
or 2 (much improved) and SCL-90-R improvement of
at least 1 SD. Patients who, regardless of the reason,
completed fewer than five sessions in the first 8
weeks or terminated treatment between Week 8 and
Week 24 were considered dropouts, with the excep-
tion of those who terminated after Week 20 (i.e.,
after 14 of the 16 psychotherapy sessions) if they had
achieved a HAM-D score of 512.
Statistical Analysis
To test for the overall effectiveness of the treatments,
within-group effects of time were calculated between
Weeks 0 and 24 using paired t tests. Analyses of
covariance (ANCOVAS) were used to test between-
group differences in terms of means, including
baseline measures as covariants. Pearson chi-square
calculations (two-sided, level of significance.05)
were used to compare refusal rates, dropout rates,
and success rates between therapy conditions. A per
protocol analysis was performed for outcome mea-
sures. This means that the outcome data of all
patients allocated to a treatment option were used
and the last observation carried forward procedure
applied in the case of missing data. The study was
divided into two parts*the first phase from start to 8
weeks and the second phase from Weeks 8 to 24*to
specifically examine the BP and sequential aspects of
the design. Between-group analyses were performed
on the whole sample of Week 0 and on the per
protocol sample of Week 8 separately, thus excluding
patients who dropped out before Week 8 and never
were offered to combine SPSP with an antidepres-
sant. A general linear model repeated measures
analysis (GLM procedure in SPSS) using all data
was performed. HAM-D outcomes of all assess-
ments were entered as dependent variables and
treatment condition (randomisation or BP) as in-
dependent variable. Use of antidepressants (yesno)
and dropout (yesno) were entered as covariates.
Finally, a separate logistic regression analysis was
conducted to test the efficacy of addition in all early
nonresponding patients.
Results
Baseline Characteristics
There were no baseline differences between rando-
mized and BP patients in demographic and clinical
characteristics (Table I). The mean age was 35.9
years (SD10.4), 79.8% of the sample were
women. About half of patients had been treated
earlier in the present episode, indicating refractory
depression.
Phase 1: Weeks 08
Of the 59 patients in the RCT condition, 19 (32.2%)
were considered study dropouts (i.e., attended fewer
than five sessions SPSP) compared with 15 (25%) of
60 in the BP group, x2(1, N119)1.46, p.23.
Subsequently, 40 originally randomized patients and
45 BP patients proceeded to the second phase of the
study.
After the first 8 weeks, 11 of 40 (27.5%)
randomized patients were responsive (30% reduc-
tion on the HAM-D) in the RCT condition com-
pared with 17 of 45 (37.8%) in the BP group.
The difference was not statistically significant. Also,
none of the secondary outcome measures differed
between RCT and BP patients with the exception of
the CGI-S, which was in favor of the BP patients,
x2(1, N85)4.83, p.03.
Phase 2: Weeks 824
The distribution of patients at 8 weeks is shown in
Figure 1.
Early responsive patients. All early responders
continued treatment of SPSP without being offered
medication. The results of mean HAM-D scores are
shown in Figure 2. For RCT patients, the mean
HAM-D score in responders had decreased from
20.4 (SD3.8) at baseline to 9.3 (SD4.1) at Week
8 and for BP patients from 19.6 (SD3.9) to 8.6
(SD8.6). The mean HAM-D scores declined only
slightly further in the second phase: for RCT
Short-term psychodynamic supportive psychotherapy 207
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patients to 7.6 (SD5.1) and for BP patients to 7.8
(SD7.9).
Table II shows the success rates on the HAM-D,
CGI, and SCL-90-R Depression scale for early
responders. In total, 71.4% of all early responding
patients achieved response and 57.1% achieved
remission. No statistically significant differences
were found between RCT and BP patients.
Early nonresponsive patients. All early nonrespon-
ders were offered to combine psychotherapy with
venlafaxine. Of the 29 RCT patients who were
nonresponsive, 17 (58.6%) started venlafaxine, and
in the BP condition only 8 of 28 patients (28.6%)
did so, x2(1, N57)5.22, p.02.
The following results concern the whole group,
regardless of acceptance of medication. At Week 8,
the mean HAM-D scores of nonresponders was still
20.6 (SD4.6) for the RCT patients and 19.6
(SD4.1) for the BP patients. As shown in Figure
II, at the end of treatment the mean HAM-D score
in RCT patients had improved to 11.4 (SD6.7)
and in BP patients to 12.5 (SD6.8).
Of all early nonresponders, 43.9% achieved res-
ponse and 26.7% achieved remission (see Table II).
At the end of treatment, no difference was found
between RCT and BP patients on any of the
outcome measures. During treatment, no difference
was found either with the exception of the therapist
rated CGI-S score at Weeks 8 and 16.
Relative Efficacy at the End of Treatment for
the Total Sample
Dropout rate in the second phase was relatively low:
six in the RCT group (15%) and four (9%) in the BP
group, x2(1, N85)0.76, p.38. The mean
HAM-D score at the end of treatment, including
both early responsive and nonresponsive patients,
was 10.3 (SD6.5) for RCT patients and 10.7
(SD7.5) for BP patients. Table II shows also the
Table I. Baseline Characteristics of Randomized and By-
Preference Patient Sample
Variable
RCT
(n59)
BP
(n60)
Total
(n119)
Gender (%)
Male 25.4 15.0 20.2
Female 74.6 85.0 79.8
Age (%)
2029 years 32.2 45.0 38.7
3039 years 35.6 25.0 30.3
]40 years 32.8 30.0 31.3
Marital status (%)
Married 24.1 23.7 23.9
Divorced 12.1 8.5 10.3
Widowed 3.4 3.4 3.4
Never married 60.3 64.4 62.4
Educational level (%)
Low 24.1 22.0 23.0
Intermediate 50.0 44.1 46.9
High 25.9 33.9 30.1
Duration of present episode (%)
B1 year 48.2 50.9 49.5
1 year 51.8 49.1 50.5
Any earlier treatment in present episode (%)
Yes 48.6 50.9 47.3
No 56.4 49.1 52.7
Earlier antidepressant use in present episode (%)
Yes 30.4 36.8 33.6
No 69.6 63.2 66.4
Recurrence (%)
0 48.2 54.2 51.3
]1 51.8 45.8 44.7
HAM-D (M9SD) 20.4 (3.8) 19.6 (3.9) 20.0 (3.8)
CGI-S (M9SD) 4.4 (0.7) 4.2 (0.8) 4.3 (0.8)
SCL-D (M9SD) 51.8 (10.0) 49.8 (12.0) 50.8 (11.0)
Note. RCTrandomized controlled trial; BPby preference;
HAM-DHamilton Rating Scale for Depression; CGI-SClin-
ical Global Impression of severity; SCL-DSymptom Checklist-
90-RDepression.
RCT
Psychotherapy
N=40
Responders  N=11
Nonresponders   N=29
Medication:
 -Addition          N=17
 -No addition     N=12
Nonresponders  N=28
Medication:
 -Addition         N= 8
 -No addition    N=20
Responders  N=17
By preference
Psychotherapy
N=45
Figure 1. Flow diagram of the treatment algorithm from Week 8.
(RCTrandomized controlled trials.)
Figure 2. Mean scores of Hamilton Depression Rating Scale in
time for patient with and without early response.
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aggregated success rates of the treatment algorithm.
In total, 52.9% of the patients achieved response and
36.5% achieved remission. The only statistical
difference appeared at Week 8 for the CGI-S
favouring BP patients. This difference disappeared
in the continuation phase of therapy. No other
differences were found throughout the entire treat-
ment. In addition, a repeated measures analysis
using all available data was performed and did not
yield a statistically significant association of treat-
ment condition and outcome (F0.997, p.41).
Efficacy of Addition of Medication
In a logistic regression analysis, we explored the
contribution of the addition of medication to treat-
ment efficacy in all early nonresponding patients.
HAM-D scores, treatment group, addition status,
and the Treatment GroupAddition Status inter-
action were entered as variables in the analysis. No
main effect for addition was found. Similarly, no
Treatment GroupAddition Status was found,
implying that the extent to which patients benefited
from additional medication was similar for the
randomized and BP conditions.
Discussion
This article reported on a partially randomized
preference trial with a sequential strategy for the
treatment of depression. Because few patients chose
to start with an antidepressant, it is only possible to
report on the comparison between randomized and
BP psychotherapy patients.
Patients’ Preference
Patients allocated to psychotherapy by chance and
those choosing psychotherapy did not differ on
baseline characteristics, thus indicating that the
process of randomisation did not create a specifically
selected group of depressed patients not willing to
accept random allocation. These results appear to be
in line with a comparable preference trial conducted
in primary care, in which no clear selection bias was
found, not even with regard to personality factors
(Bedi et al., 2000).
Almost all patients in the BP modality chose to
start with psychotherapy and not with an antide-
pressant. In a systematic review, a preference for
psychotherapy was found in all available studies (van
Schaik et al., 2004), but such a strong preference has
Table II. Success Rates (%) of Early Responders, Early Nonresponders, and Total Sample in RCT and BP Patients
Early responders Early nonresponders Total sample
Measurement
RCT
(n11)
BP
(n17)
Total
(n28)
RCT
(n29)
BP
(n28)
Total
(n57)
RCT
(n40)
BP
(n45)
Total
(n85)
HAM-D
Response (50%¡)
Week 8 45.5 58.8 53.6 NA NA NA 12.5 22.2 17.6
Week 16 36.4 70.6 57.1 24.1 21.4 22.8 27.5 40.0 34.1
Week 24 63.6 76.5 71.4 55.6 43.9 43.9 57.5 48.9 52.9
HAM-D
Remission (57)
Week 8 36.4 41.2 39.6 NA NA NA 10.0 15.6 12.9
Week 16 36.5 52.9 46.4 18.8 14.3 14.0 20.0 28.9 24.7
Week 24 54.5 58.8 57.1 27.6 26.3 26.7 35.0 37.8 36.5
CGI-Severity
Week 8 36.4 58.8 39.3 0.0* 17.9* 8.8 10.0* 33.3* 22.9
Week 16 54.5 82.4 46.4 37.9* 14.3* 26.3 42.5 40.0 41.2
Week 24 81.8 76.5 57.1 55.2 46.4 50.9 62.5 57.8 60.0
CGIImprovement
Week 8 36.4 52.9 50.0 10.3 14.3 12.3 17.5 28.9 23.5
Week 16 45.5 76.5 71.4 34.5 17.9 26.3 37.5 40.0 38.8
Week 24 72.7 76.5 78.6 55.2 53.6 54.4 60.0 62.2 61.2
SCL-D (1 SD ¡)
Week 8 40.0 58.8 51.9 21.4 11.1 16.4 26.3 29.5 28.0
Week 16 80.0 64.7 70.4 57.1 37.0 47.3 63.2 47.7 54.9
Week 24 80.0 64.7 70.4 64.3 48.1 56.4 68.4 54.5 61.0
Note. RCTrandomized controlled trial; BPby preference; HAM-DHamilton Rating Scale for Depression; CGIClinical Global
Impression; SCL-DSymptom ChecklistDepression; NAnot applicable because of definition of nonresponse.
*pB.05.
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not been reported before. However, unlike other
studies, it should be taken into account that in our
treatment algorithm patients knew from the start
that they would be offered augmentation of an
antidepressant if the therapy was not working after
2 months, which might have influenced their choice.
Remarkably, at present, the situation in the United
States appears to have changed. Despite the growing
evidence of the efficacy of antidepressant psy-
chotherapies, the recently emerging STAR*D data
suggest that psychotherapy is no longer the treat-
ment of choice for American patients (Wisniewski
et al., 2007). This may reflect cultural variation but
also points to a limited accessibility of psychotherapy
for depression in the current American health care
systems (Weissman, 2007).
In the current study, many patients declined an
additional antidepressant after 8 weeks, not surpris-
ingly within the BP group more so than within the
RCT group. Apparently, they preferred to continue
with psychotherapy alone in spite of early nonre-
sponse. Obviously, we do not know to what extent
this is typical for the patient population that has been
studied. Again, in the United States, patients seem
to choose rather differently. In a study on IPT,
almost every patient with poor response accepted the
addition of an antidepressant (Frank et al., 2000).
We cannot rule out that, compared with SPSP, the
IPT model is more to amenable to the integration of
medication, which might have contributed to this
difference. However, in SPSP also, depression is
primarily considered as a medical condition that, if
necessary, should be treated with medication. This is
illustrated by an earlier finding showing that patients
in combined therapy were more compliant with the
medication regimen than patients using antidepres-
sants alone (de Jonghe, Kool, Dekker, & Peen,
2001), suggesting a good acceptance of pharma-
cotherapy during SPSP. We, therefore, hypothesise
that the difference in acceptability of antidepressants
may reflect a more general positive attitude to
medication in U.S. patients. It raises questions about
the cross-cultural feasibility of sequential treatment
strategies consisting of both psychotherapy and
antidepressants, which need to be taken into account
in guidelines and the application of treatment algo-
rithms in clinical practice.
About one third of the patients did not complete
the psychotherapy as planned. In earlier studies,
both in our settings and those of others, comparable
dropout rates were found (see, e.g., Blom, 2007;
de Jonghe et al., 2004). Therefore, we assume it
could be interpreted as a general characteristic of
secondary care depressed patients. In contrast to
what might be expected, choosing treatment did not
enhance adherence to psychotherapy because drop-
out rates did not differ between RCT and BP
patients, not even in the initial phase of treatment,
shortly after they had made their choice. Clearly, a
better understanding of the background of this
phenomenon is important. It may indicate a need
to try other strategies. Possibly, techniques derived
from motivational interviewing (Cheng, 2007) are
useful to improve adherence, particularly in the
initial phase where most dropouts occurred.
In terms of general efficacy, patients in both
conditions improved equally well on all instruments
throughout the treatment period. Having a prefer-
ence for psychotherapy did not convey a benefit in
response. A similar absence of a profound influence
of preference on outcome has been reported in two
earlier trials (van Schaik et al., 2004). It refutes the
assumption that randomisation may lead to an
underestimation of efficacy as a result of unjustly
neglecting patients’ preference or the possibility of
including less motivated patients in treatment
(Thornett, 2001).
Sequential Strategy
If we look at the pattern of HAM-D response during
treatment (see Figure II), two groups of patients can
be identified: early responders (i.e., patients who
improved rapidly) and delayed responders (i.e.,
those who started to improve in the second phase
of treatment). This confirms a pattern of response
we found in an earlier trial with SPSP (Van et al.,
2008).
It suggests that it may be worthwhile to continue
an ongoing psychotherapeutic strategy despite ap-
parent absence of early symptom improvement. After
all, a considerable number of patients do respond
later on. In our study, the second phase consisted of
eight sessions over a 4-month period. Unfortunately,
we were not able to answer the question whether,
after this second phase, again a group of nonre-
sponding patient could be identified that might
benefit from a further continuation of treatment.
Future studies, preferably including ongoing re-
sponse-monitoring procedures during psychotherapy
(Percevic, Lambert, & Kordy, 2006), are required to
shed more light on this issue.
It could be questioned whether it would have been
necessary for early responders to continue therapy
after Week 8. Because the mean HAM-D had already
diminished to 9.0 by that time, there is little room for
further symptom improvement. However, in SPSP
the therapeutic process is structured in discourse
levels (de Jonghe, 2005). This means that, in the
initial phase, the therapy focuses on coping with
symptoms and on (life) circumstances or problems
directly related to the depression. If improvement at
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this level has been achieved, the therapist may
proceed to work on intrapersonal vulnerabilities in
the middle and late stages of therapy, related to the
onset of depression.
Preliminary data suggest that a change in person-
ality pathology indeed could be achieved after SPSP
(Kool et al., 2003). In future research, it would,
therefore, be of interest to explore whether this in
particular occurs in early symptom responders,
because in these patients the therapist is better able
to focus on underlying personality vulnerabilities. If
so, this would legitimize a (time-limited) continua-
tion of psychotherapy.
Strengths
We adopted a by-preference sequential strategy. This
relatively rare design can illuminate what occurs in
regular clinical practice because many patients prefer
to choose their treatment, if possible. Furthermore,
sequential treatment strategies appear to be widely
advocated and used in clinical settings (Schatzberg
et al., 2005) but rarely investigated. Therefore, using
this strategy, we intended to increase the external
validity of our study. A further strength is that
outcome data came from three different sources:
independent observers, patients, and therapists.
Finally, many patients had been treated before in
the present depressive episode, indicating they
suffered from refractory depressions. Also, patients
were not specifically selected for psychotherapy.
Therefore, they may be representative of the broad
sample of difficult-to-treat depressed patients com-
monly referred to outpatient psychiatric facilities.
Limitations
Our study involves outpatients with moderately
severe depression; thus, the findings may not gen-
eralize to more or less severely depressed patients.
Also, we did not take into account the influence of
personality factors or attitude toward treatment,
which might be associated with both the accept-
ability and efficacy of psychotherapeutic strategies
(Iacoviello et al., 2007). Although additional medi-
cation could not explain subsequent outcome, it
should be noted that the nonresponding patients
were not randomized at Week 8. Therefore, it
remains possible that they would have done poorer
without medication addition.
Patients were only offered two options (randomi-
zation vs. by-preference SPSP or medication). Other
antidepressant treatments such as different forms
of psychotherapy, combined therapy from the outset,
psychosocial support, and long-term psychothe-
rapy could not be chosen, thereby limiting the
generalizability to settings in which these treatments
are offered. Finally, although a clear influence of
choosing treatment could not be demonstrated in
any of the statistical analyses, it needs to be taken
into account that the groups were relatively small for
the amount of measurements. Therefore, the occur-
rence of Type II errors cannot be ruled out.
Conclusion
This study indicated that patients who actively
choose had outcomes similar to those who were
randomly allocated to psychotherapy. In addition, no
clear surplus value for a sequential strategy of adding
medication after early nonresponse could be demon-
strated. In contrast, a (time limited) and monitored
continuation of the same psychotherapeutic strategy
may be warranted in these patients because a
considerable number do have a delayed response.
References
American Psychiatric Association. (1994). Diagnostic and statistical
manual of mental disorders (4th ed.). Washington, DC: Author.
Arrindell, W. A., & Ettema, J. M. M. (1986). Handleiding bij
een multidimensionele psychopathologie-indicator [Manual of
measuring multidimensional psychopathology]. Lisse, The
Netherlands: Swets & Zeitlinger.
Bedi, N., Chilvers, C., Churchill, R., Dewey, M., Duggan, C.,
Fielding, K., et al. (2000). Assessing effectiveness of treatment
of depression in primary care: Partially randomized preference
trial. British Journal of Psychiatry, 177, 312318.
Blom, M. B. J. (2007). Combination treatment for depressed out-
patients: Efficacy and prediction of outcome. Amsterdam: Vrije
University.
Brewin, C. R., & Bradley, C. (1989). Patient preferences and
randomized clinical trials. British Medical Journal, 299,
313315.
Casacalenda, N., Perry, J. C., & Looper, K. (2002). Remission in
major depressive disorder: A comparison of pharmacotherapy,
psychotherapy and control conditions. American Journal of
Psychiatry, 159, 13541360.
Cheng, M. (2007). New approaches for creating the therapeutic
alliance: Solution-focused interviewing, motivational interview-
ing, and the medication interest model. Psychiatric Clinics of
North America, 30, 157166.
de Jonghe, F. (1994). Leidraad voor het scoren van de Hamilton
Depression Rating Scale. Amsterdam: Benecke Consultants.
de Jonghe, F. (2005). Kort en Krachtig [Brief and potent].
Amsterdam: Benecke N.I.
de Jonghe, F., Hendriksen, M., van Aalst, G., Kool, S., Peen, J.,
Van, R., et al. (2004). Psychotherapy and combined therapy
(pharmacotherapy plus psychotherapy) in the treatment of
depression. British Journal of Psychiatry, 185, 3745.
de Jonghe, F., Kool, S., van Aalst, G., Dekker, J., & Peen, J.
(2001). Combining psychotherapy and antidepressants in the
treatment of depression. Journal of Affective Disorders, 64,
217229.
de Maat, S., Dekker, J., Schoevers, R., van Aalst, G., Hendriksen,
M., Kool, S., et al. (2008). Short psychodynamic supportive
psychotherapy, antidepressants, and their combination in the
treatment of major depression: A mega-analysis based on three
randomized clinical trials. Depression and Anxiety, 25, 565574.
Short-term psychodynamic supportive psychotherapy 211
D
o
w
n
lo
ad
ed
 B
y:
 [
Vr
ij
e 
Un
iv
er
si
te
it
, 
Li
br
ar
y]
 A
t:
 1
2:
40
 2
6 
No
ve
mb
er
 2
01
0
de Maat, S., Dekker, J., Schoevers, R., & de Jonghe, F. (2006).
Relative efficacy of psychotherapy and pharmacotherapy in the
treatment of depression: A meta-analysis. Psychotherapy
Research, 16, 562572.
Dekker, J., Koelen, J. A., Van, H. L., Schoevers, R. A., Peen, J.,
Hendriksen, M., et al. (2008). Speed of action: The efficacy of
short-term psychodynamic supportive psychotherapy versus
pharmacotherapy in the treatment of depression: Part I. The
first 8 weeks of treatment. Journal of Affective Disorders, 109,
183188.
Dekker, J., Van, H. L., Schoevers, R. A., Koelen, J. A., van Aalst,
G., Peen, J., et al. (2008). Efficacy of short-term psychodynamic
supportive psychotherapy and pharmacotherapy in a treatment
algorithm for depression. Manuscript submitted for publication.
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C.,
Young, P. R., Salomon, R. M., et al. (2005). Cognitive therapy
versus medications in the treatment of moderate to severe
depression. Archives of General Psychiatry, 62, 409416.
Frank, E., Grochocinski, V. J., Spanier, C. A., Buysse, D. J.,
Cherry, C. R., Houck, P. R., et al. (2000). Interpersonal
psychotherapy and antidepressant medication: Evaluation of a
sequential treatment strategy in women with recurrent major
depression. Journal of Clinical Psychiatry, 61, 5157.
Gabbard, G. (2005). Psychodynamic psychiatry in clinical practice.
Arlington, VA: American Psychiatric Publishing, Inc.
Guy, W. (1976). ECDEU assessment manual for psychopharmacology
(revised) (U.S. Department of Health, Education and Welfare
Pub. ADM 76-338, 218-222). Rockville, MD: National
Institute of Mental Health.
Hamilton, M. (1967). Development of a rating scale for primary
depressive illness. British Journal of Social and Clinical Psychol-
ogy, 6, 278296.
Howard, L., & Thornicroft, G. (2006). Patient preference
randomised controlled trials in mental health research. British
Journal of Psychiatry, 188, 303304.
Iacoviello, B. M., McCarthy, K. S., Barrett, M. S., Rynn, M.,
Gallop, R., & Barber, J. P. (2007). Treatment preferences affect
the therapeutic alliance: Implications for randomized con-
trolled trials. Journal of Consulting and Clinical Psychology, 75,
194198.
Kool, S., Dekker, J., Duijsens, I. J., de Jonghe, F. & Puite, B.
(2003). Changes in personality pathology in depressed patients
with pharmacotherapy and combined therapy. Journal of
Personality Disorders, 17, 6072.
Parker, G. (2005). Beyond major depression. Psychological Med-
icine, 35, 467474.
Percevic, R., Lambert, J., & Kordy, H. (2006). What is the
predictive value of response to psychotherapy for its future
course? Empirical explorations and consequences for outcome.
Psychotherapy Research, 16, 364373.
Rothwell, P. M. (2005). External validity of randomised con-
trolled trials: ‘‘To whom do the results of this trial apply?’’ The
Lancet, 365, 8293.
Schatzberg, A. F., Rush, A. J., Arnow, B. A., Banks, P. L. C.,
Blalock, J., Boriam, F., et al. (2005). Chronic depression.
Archives of General Psychiatry, 62, 513520.
Thornett, A. (2001). Assessing the effect of patient and prescriber
preference in trials of treatment of depression in general
practice. Medical Science Monitoring, 7, 10861091.
Van, H. L., Schoevers, R., Peen, J., Kool, S., Hendriksen, M., &
Dekker, J. (2008). Does early response predict outcome in
psychotherapy and combined therapy for major depression?
Journal of Affective Disorders, 105, 261265.
van Schaik, D., Klijn, A., van Hout, H., Marwijk, H. W. J.,
de Haan, M., & van Dyck, R. (2004). Patients’ preference in
the treatment of depressive disorder in primary care. General
Hospital Psychiatry, 26, 184189.
Weissman, M. M. (2007). Cognitive therapy and interpersonal
psychotherapy: 30 years later. American Journal of Psychiatry,
164, 693696.
Westen, D., Novotny, C. M., & Thompson-Brenner, H. (2004).
The empirical status of empirically supported psychotherapies:
Assumptions, findings, and reporting in controlled clinical
trials. Psychological Bulletin, 130, 631663.
Wisniewski, S. R., Fava, M., Trivedi, M. H., Thase, M. E.,
Warden, D., Niedere, G., et al. (2007). Acceptability of second-
step treatments to depressed outpatients: A STAR*D report.
American Journal of Psychiatry, 164, 753760.
212 H. L. Van et al.
D
o
w
n
lo
ad
ed
 B
y:
 [
Vr
ij
e 
Un
iv
er
si
te
it
, 
Li
br
ar
y]
 A
t:
 1
2:
40
 2
6 
No
ve
mb
er
 2
01
0
